$BVFL

Director trims BV Financial (BVFL) stake with 5,000-share sale

BV Financial director Joseph S. Galli sold 5,000 shares of common stock on May 8, 2026, through an IRA at prices of $20.03 and $20.00 per share. After the transactions, his indirect IRA holdings are 31,341 shares, a retirement plan holds 12,100 shares, and he directly holds 80,309 shares. He also retains stock options for 36,746 shares with a $14.25 exercise price, vesting at 25% annually starting September 6, 2025.

Original reporting
Published May 12, 2026, 12:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 12, 2026, 12:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$BVFL
Bearish
medium confidence
Mentioned
$BVFL
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$BVFLBearishLow
01

Why it matters

The sale is a small portion of his holdings and may not reflect broader company performance.

02

Market read

The insider sale has limited immediate impact on the stock's market perception.

03

What to watch

Other insider holdings and company fundamentals should be considered before making trading decisions.

Relevance 6/10Timing: short-term

Background

BV Financial's insider, Joseph S. Galli, sold 5,000 shares at around $20, possibly reflecting personal financial planning rather than company outlook.

Company-level read

Ticker impact

$BVFLBearishMedium confidence
Context

The news involves insider stock sale by a director, which may signal insider sentiment but is limited in scope.

Expected impact

Potential short-term slight decline or sideways movement; long-term impact uncertain.

Evidence & confidence

Insider sales can be routine or strategic; without additional context, the impact remains limited.

Market effects

Limited sector impact; no significant changes indicated.

Minimal regional effects expected.

Negligible global market relevance.

Counterpoint

Insider sales do not necessarily indicate negative outlook; they could be for personal liquidity or diversification.

Key entities

  • BV Financial

    A financial services company traded publicly.

  • Joseph S. Galli

    Director of BV Financial, involved in the stock sale.

Related articles

$BVFLLow

BV FINANCIAL, INC. ANNOUNCES FINANCIAL RESULTS

BV Financial, Inc. (BVFL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Michael J. Dee Chief Financial Officer (410) 477- 5000 BV FINANCIAL, INC. ANNOUNCES FINANCIAL RESULTS Baltimore, Maryland, October 23, 2026– BV Financial, Inc. (NASDAQ: BVFL), the holding company for BayVanguard Bank (the “Bank”), today reported net income o

$BVFLMed

BV FINANCIAL, INC. ANNOUNCES FINANCIAL RESULTS

BV Financial, Inc. (BVFL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bvfl-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Contact: Michael J. Dee Chief Financial Officer (410) 477- 5000 BV FINANCIAL, INC. ANNOUNCES FINANCIAL RESULTS Baltimore, Maryland, July 24, 2026– BV Financial, Inc. (NASDAQ: BVFL), the holding company for BayVanguard Bank (t

$BMYMed

Bristol Myers Squibb Reports CAR T-Cell Therapy Data In Multiple Sclerosis

Bristol Myers Squibb (BMY) reported interim Phase 1 Breakfree-2 study results for its CAR T-cell therapy zolacabtagene autoleucel in 66 multiple sclerosis patients. 92% of progressive MS patients showed stable or improved disability. Safety issues included cytokine release syndrome in 42.4% of patients. BMY stock is down 2.26% at $61.56.